Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stroke Prevention in Patients With Atrial Fibrillation Clear all
Terminated Phase 2 Interventional

Long Term Open Follow-up With H376/95 vs. Warfarin

NCT00206063
View directory record Official record
Conditions
Stroke Prevention in Patients With Atrial Fibrillation
Interventions
EXANTA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Sep 30, 2026, 5:41 PM EDT
Not yet recruiting Not applicable Interventional

Computerized Decision Support to Prevent Stroke in Atrial Fibrillation

NCT06355986
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Alert-based computerized decision support
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the Field

NCT01090362
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years and older
Enrollment
57,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

NCT02339493
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Computer Electronic Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 30, 2026, 5:41 PM EDT
Recruiting Phase 4 Interventional

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

NCT03968393
View directory record Official record
Conditions
Stroke, Atrial Fibrillation
Interventions
Non-vitamin K oral anticoagulant (NOAC)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
2,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

NCT03374540
View directory record Official record
Conditions
Nonvalvular Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
78,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Multiple Locations, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

NCT01227629
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dabigatran with ASA, warfarin, dabigatran without ASA
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
14
States / cities
Fayetteville, Arkansas • La Mesa, California • Pensacola, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 30, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional

Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

NCT05723926
View directory record Official record
Conditions
Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Interventions
Vine Filter
Device
Lead sponsor
Javelin Medical
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Rockford, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stroke Feasibility Study

NCT01997905
View directory record Official record
Conditions
Atrial Fibrillation, AFib
Interventions
AtriClip LAA Exclusion Device
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 30, 2026, 5:41 PM EDT